Case Funding has recently expanded its lawsuit funding solutions to cover Topamax cases, broadening the finance options we provide to both lawyers and plaintiffs embroiled in dangerous drug litigation.
As some of the first Topamax lawsuits are now being resolved, Janssen Pharmaceuticals (a division of Johnson & Johnson) is coming under an increasing amount of pressure to settle the hundreds of cases it is currently facing before these lawsuits proceed to trial. In a Philadelphia court alone, more than 130 Topamax lawsuits have reportedly been filed against Janssen based on claims that the use of the Topamax anticonvulsant drug during pregnancy caused some babies to be born with cleft palate, cleft lip and other injuries.
In two groundbreaking Topamax lawsuit settlements awarded at the end of 2013, Janssen Pharmaceuticals was reportedly ordered to pay one family $4 million and another family $11 million due to the Topamax birth injuries their newborns sustained. In these cases, the juries agreed with the plaintiffs’ contentions that Janssen Pharmaceuticals failed to adequately warn doctors and patients about the risk of serious birth injuries associated with the use of Topamax during pregnancy. These jury decisions have set precedents for Topamax settlements that could spell trouble for Janssen if the company is unable to resolve these lawsuits prior to the trial phase.
Although Janssen Pharmaceuticals is reportedly appealing both the above-mentioned verdicts, the company will likely face an uphill battle during its appeal, as plaintiffs and their attorneys have pointed to evidence like the FDA’s Topamax warnings. to prove Janssen’s negligence. These war which have linked the use of this anticonvulsant drug to an increased risk of cleft defects that is more than 20 times greater than the risk when the drug is not taken during pregnancy.